|
 If you are looking for a Ph.D. program with dedicated, engaged and successful faculty members; a cohesive, interactive and fun student body; and an overall outstanding training opportunity, consider the Molecular Pharmacology and Experimental Therapeutics (MPET) program at Mayo Clinic for your graduate training. Specific reasons to consider MPET include:
-
Pharmacology is an exciting discipline that prepares you for success in today's biomedical research environment. The most successful biomedical scientists integrate across various disciplines to devise and answer important questions that will enhance our understanding of biology and impact the treatment of disease. The MPET program does exactly that, by training students to use biochemistry, molecular biology, genetics, cell biology and genomics to develop new therapeutic approaches to treat human diseases.
-
Your research can make a difference in patient care! If you want your research to make a difference — now or in the future — MPET is the place for you. MPET students participate in research programs that span a continuum of sophisticated, exciting and innovative basic, translational and clinical research in the areas of cancer, neurological disease, cardiovascular disease, pharmacogenomics/genetics, drug discovery, cell signaling and alcohol/drug addiction. This broad spectrum provides students with opportunities to perform basic research and participate in the translation of research findings into the clinical setting. Notably, we have many examples of a student's research findings leading to new clinical trials or directly affecting patient care, often even during the student's training period.
-
You will receive outstanding training. MPET has exceptional faculty mentors, who are not only are committed to training graduate students in the classroom and laboratory, but also direct cutting-edge research programs (as demonstrated by publications in high-impact journals such as Nature Medicine, Nature, New England Journal of Medicine, Science, Molecular Cell, EMBO Journal and other top-flight discipline-specific journals).
-
MPET students are successful. MPET students publish numerous highly cited articles (an average of more than six articles for students who earn a Ph.D. or an M.D.-Ph.D.). Upon completion of their Ph.D. training, MPET students go on to top-notch residency and postdoctoral positions at the most prestigious research institutions (e.g., Stanford, Baylor, University of Virginia, Johns Hopkins, Harvard, National Cancer Institute, Memorial Sloan Kettering, etc). And many former students are now principal investigators in academia (e.g., Emory, Louisiana State, Mayo Clinic, University of Minnesota, etc.) and industry (e.g., Amgen, AstraZeneca, etc.).
Additional evidence of MPET's success as a Ph.D. training program is demonstrated by our successful competition for a prestigious National Institutes of Health Predoctoral Training Grant to the MPET program. In the review of that application, peer reviewers noted that:
"The success of the program (MPET) is evident in the productivity of the trainees while they are in the program and the distinguished careers that they have after they have graduated. This program has numerous strengths, including a heavily funded and engaged cohort of trainers, a comprehensive didactic program, and an administration that has a demonstrated commitment to graduate education … the program is highly effective at training these students and bringing out their best. Along these lines, the MPET is a highly cohesive program with significant evidence of collaboration and numerous events that bring faculty and students together. It appears that MPET students are trained by 'a village' … Overall, this is an excellent training program and enthusiasm for this program is very, very high."
Overall, the MPET program offers unique, innovative and exceptional training opportunities that prepare students for exciting, productive and rewarding careers in biomedical science.
Larry M. Karnitz, Ph.D.
Director
Molecular Pharmacology and Experimental Therapeutics Program
|
